ketanserin has been researched along with Body Weight in 29 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventeen subjects with essential hypertension (14 men, 3 women, 40-69 years of age), 13 of whom continued their previous antihypertensive therapy, completed a double-blind crossover trial of ketanserin 40 mg twice daily versus placebo tablets twice daily." | 9.05 | Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. ( Ayres, B; Bune, AJ; Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1985) |
| "Ketanserin, an investigational, antiserotonergic agent, at a dose of 40 mg bid was given to 18 patients with mild to moderate primary hypertension in a randomized, double-blind, crossover study, with 100-mg metoprolol bid for four weeks each." | 9.05 | Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension. ( Fasano, ML; Ferrara, LA; Iannuzzi, A; Rubba, P; Soro, S, 1985) |
| "5 mg/kg) on (i) anxiety-related behaviour in an elevated plus-maze, and (ii) specific [3H]ketanserin binding at central 5-HT2A receptors, in Roman rats." | 7.69 | Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors. ( Chaouloff, F; Kulikov, A; Mormède, P, 1997) |
| "The long-term haemodynamic effects of ketanserin, a new serotonin-antagonist, was examined in 13 patients of both sexes (age range 24-62 years) with mild and moderate essential hypertension (EH)." | 7.66 | Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise. ( Lund-Johansen, P; Omvik, P, 1983) |
| " The twice daily dosage schedule caused trough blood pressure control with both drugs." | 6.66 | Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial. ( Alcocer, L; Copertari, P; Feruglio, F; Landi, E; Lopes, M; San Martin, C; Zin, C, 1987) |
| "Treatment with ketanserin caused hypotension, enhanced bradycardia, attenuated reflex tachycardia, and reversed serotonin (5-HT) responses, with all effects being more pronounced in 24-month-old rats than in younger rats." | 5.30 | Does chronic ketanserin treatment enhance bradycardia in old rats by serotonergic blockade? ( Buñag, RD; Davidow, LW, 1998) |
| " Ketanserin or slow-release nifedipine were added to the treatment of 24 patients with hypertension uncontrolled by a thiazide diuretic plus beta-adrenoceptor antagonist in an observer-blind, randomised parallel-group study of 6 months duration." | 5.06 | Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker. ( Ramsay, LE; Solomon, SA; Waller, PC, 1987) |
| "The antihypertensive effects of the 5-HT2 receptor antagonist ketanserin were evaluated in 16 patients with uncomplicated essential hypertension." | 5.06 | Antihypertensive response to ketanserin: influence of race and weight. ( Cressman, MD; Ferguson, RK; Gabos, C; Kosoglou, T; Rocci, ML; Vlasses, PH, 1988) |
| "Seventeen subjects with essential hypertension (14 men, 3 women, 40-69 years of age), 13 of whom continued their previous antihypertensive therapy, completed a double-blind crossover trial of ketanserin 40 mg twice daily versus placebo tablets twice daily." | 5.05 | Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension. ( Ayres, B; Bune, AJ; Chalmers, JP; Graham, JR; West, MJ; Wing, LM, 1985) |
| "Ketanserin, an investigational, antiserotonergic agent, at a dose of 40 mg bid was given to 18 patients with mild to moderate primary hypertension in a randomized, double-blind, crossover study, with 100-mg metoprolol bid for four weeks each." | 5.05 | Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension. ( Fasano, ML; Ferrara, LA; Iannuzzi, A; Rubba, P; Soro, S, 1985) |
| " Addition of eugenosedin-A to the high-fat diet resulted in less weight gain and reduced hyperglycaemia, hyperinsulinaemia and hyperlipidaemia." | 3.75 | Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet. ( Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN, 2009) |
| "Triiodothyronine (T3) has been shown to accelerate and potentiate the clinical response to tricyclic antidepressant (TCA) treatment in depressive disorders." | 3.71 | Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain. ( Jeanningros, R; Mazzola-Pomietto, P; Moreau, X, 2001) |
| "5 mg/kg) on (i) anxiety-related behaviour in an elevated plus-maze, and (ii) specific [3H]ketanserin binding at central 5-HT2A receptors, in Roman rats." | 3.69 | Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors. ( Chaouloff, F; Kulikov, A; Mormède, P, 1997) |
| "The long-term haemodynamic effects of ketanserin, a new serotonin-antagonist, was examined in 13 patients of both sexes (age range 24-62 years) with mild and moderate essential hypertension (EH)." | 3.66 | Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise. ( Lund-Johansen, P; Omvik, P, 1983) |
| " The twice daily dosage schedule caused trough blood pressure control with both drugs." | 2.66 | Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial. ( Alcocer, L; Copertari, P; Feruglio, F; Landi, E; Lopes, M; San Martin, C; Zin, C, 1987) |
| " Chronic administration of mCPP (1-(m-chlorophenyl)piperazine) (2 mg/kg bid, i." | 1.31 | Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. ( Arjona, AA; Lee, RK; Pooler, AM; Wurtman, RJ, 2002) |
| "Treatment with ketanserin caused hypotension, enhanced bradycardia, attenuated reflex tachycardia, and reversed serotonin (5-HT) responses, with all effects being more pronounced in 24-month-old rats than in younger rats." | 1.30 | Does chronic ketanserin treatment enhance bradycardia in old rats by serotonergic blockade? ( Buñag, RD; Davidow, LW, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (51.72) | 18.7374 |
| 1990's | 9 (31.03) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 2 (6.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, X | 1 |
| Zhang, Y | 1 |
| Chen, Y | 1 |
| Qiu, Y | 1 |
| Yu, M | 1 |
| Xu, X | 1 |
| Liu, X | 1 |
| Liu, BF | 1 |
| Zhang, L | 1 |
| Zhang, G | 1 |
| Shen, KP | 1 |
| Lin, HL | 1 |
| Hsieh, SL | 1 |
| Kwan, AL | 1 |
| Chen, IJ | 1 |
| Wu, BN | 1 |
| Abe, C | 1 |
| Tanaka, K | 1 |
| Iwata, C | 1 |
| Morita, H | 1 |
| Arjona, AA | 1 |
| Pooler, AM | 1 |
| Lee, RK | 1 |
| Wurtman, RJ | 1 |
| Fonseca, V | 1 |
| Ramage, AG | 1 |
| Mikhailidis, DP | 1 |
| Barradas, MA | 1 |
| Jeremy, JY | 1 |
| Dandona, P | 1 |
| Omvik, P | 1 |
| Lund-Johansen, P | 1 |
| Sikorski, BW | 1 |
| James, GM | 2 |
| Glance, SD | 1 |
| Hodgson, WC | 2 |
| King, RG | 1 |
| Darlametsos, I | 1 |
| Morphake, P | 1 |
| Bariety, J | 1 |
| Hornych, A | 1 |
| Tsipas, G | 1 |
| Gkikas, G | 1 |
| Papanikolaou, N | 1 |
| Kaminski, D | 1 |
| Weiner, N | 1 |
| Sturm, G | 1 |
| Wesemann, W | 1 |
| Van Diest, MJ | 1 |
| Verbeuren, TJ | 1 |
| Herman, AG | 1 |
| Okuyama, N | 1 |
| Morinobu, S | 1 |
| Totsuka, S | 1 |
| Endoh, M | 1 |
| Chaouloff, F | 1 |
| Kulikov, A | 1 |
| Mormède, P | 1 |
| Buñag, RD | 1 |
| Davidow, LW | 1 |
| Moreau, X | 1 |
| Jeanningros, R | 1 |
| Mazzola-Pomietto, P | 1 |
| Lavezzaro, G | 1 |
| Ladetto, PE | 1 |
| Valente, M | 1 |
| Stramignoni, D | 1 |
| Zanna, C | 1 |
| Assogna, G | 1 |
| Salvetti, A | 1 |
| Staessen, J | 3 |
| Fagard, R | 3 |
| Fiocchi, R | 1 |
| Lijnen, P | 3 |
| Rorive, G | 3 |
| Amery, A | 3 |
| Wing, LM | 1 |
| Chalmers, JP | 1 |
| West, MJ | 1 |
| Bune, AJ | 1 |
| Ayres, B | 1 |
| Graham, JR | 1 |
| Hannedouche, T | 1 |
| Fillastre, JP | 1 |
| Mimran, A | 1 |
| de Tréglodé, D | 1 |
| Schardt, F | 1 |
| Rosenthal, T | 1 |
| Grossman, E | 1 |
| Rocco, S | 1 |
| Zin, C | 1 |
| Copertari, P | 1 |
| Landi, E | 1 |
| San Martin, C | 1 |
| Lopes, M | 1 |
| Feruglio, F | 1 |
| Alcocer, L | 1 |
| Blaton, V | 1 |
| Hollez, P | 1 |
| Kalkman, HO | 1 |
| Neumann, V | 1 |
| Brauner, V | 1 |
| Fasano, ML | 2 |
| Soro, S | 2 |
| Ferrara, LA | 2 |
| Cross, JA | 1 |
| Horton, RW | 1 |
| Waller, PC | 1 |
| Solomon, SA | 1 |
| Ramsay, LE | 1 |
| Kosoglou, T | 1 |
| Cressman, MD | 1 |
| Vlasses, PH | 1 |
| Rocci, ML | 1 |
| Gabos, C | 1 |
| Ferguson, RK | 1 |
| Rubba, P | 1 |
| Iannuzzi, A | 1 |
| Janssens, M | 1 |
| Symoens, J | 1 |
12 trials available for ketanserin and Body Weight
| Article | Year |
|---|---|
Ketanserin and captopril interaction in the treatment of essential hypertensives.
Topics: Adult; Aldosterone; Blood Pressure; Body Weight; Captopril; Double-Blind Method; Drug Therapy, Combi | 1990 |
Double-blind comparison of ketanserin with propranolol in hypertensive patients: interim report.
Topics: Adult; Aged; Antihypertensive Agents; Body Weight; Clinical Trials as Topic; Double-Blind Method; Fe | 1985 |
Effect of ketanserin on blood pressure and biochemical parameters in patients with essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clin | 1985 |
Ketanserin versus nifedipine in the treatment of essential hypertension in patients over 50 years old: an international multicenter study.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Female; Flushing; Heart Rate; Humans; Hyperte | 1987 |
Evaluation of a new antihypertensive agent ketanserin versus methyldopa in the treatment of essential hypertension in older patients: an international multicenter trial.
Topics: Blood Pressure; Body Weight; Central Nervous System; Clinical Trials as Topic; Female; Heart Rate; H | 1987 |
Serum cholesterol during ketanserin and propranolol administration in hypertensive patients.
Topics: Body Weight; Cholesterol; Female; Heart Rate; Humans; Hypertension; Ketanserin; Lipoproteins, HDL; L | 1987 |
Double-blind comparison of ketanserin and propranolol in hypertensive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Blood Pressure; Body Weight; Chromatography, High | 1988 |
Long-term antihypertensive efficacy of ketanserin plus chlorthalidone.
Topics: Adult; Aged; Blood Pressure; Body Weight; Chlorthalidone; Clinical Trials as Topic; Drug Administrat | 1989 |
Comparison of ketanserin and slow-release nifedipine added to the treatment of hypertensive patients uncontrolled by a thiazide diuretic plus beta-adrenoceptor blocker.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Benzothiadiazines; Blood Pressure; Body Weight; Clinical T | 1987 |
Antihypertensive response to ketanserin: influence of race and weight.
Topics: Adult; Aged; Aldosterone; Black People; Blood Pressure; Body Weight; Female; Heart Rate; Humans; Hyp | 1988 |
Cardiovascular effects of ketanserin, a new antiserotonergic agent in the treatment of arterial hypertension.
Topics: Adult; Blood Pressure; Body Weight; Exercise Test; Heart Rate; Hemodynamics; Humans; Hypertension; K | 1985 |
Ketanserin compared to nifedipine and methyldopa in patients aged above 50 years: two international multicentre studies. For the International Study Group.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Heart Rate | 1986 |
17 other studies available for ketanserin and Body Weight
| Article | Year |
|---|---|
Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.
Topics: Animals; Antipsychotic Agents; Body Weight; Chemistry Techniques, Synthetic; Drug Design; Ether-A-Go | 2018 |
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glut | 2009 |
Vestibular-mediated increase in central serotonin plays an important role in hypergravity-induced hypophagia in rats.
Topics: Animals; Arsanilic Acid; Body Weight; Drinking; Eating; Feeding Behavior; Hypergravity; Ketanserin; | 2010 |
Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Body Weight; Brai | 2002 |
Ketanserin in intermittent claudication.
Topics: Appetite; Blood Pressure; Body Weight; Humans; Intermittent Claudication; Ketanserin; Piperidines | 1984 |
Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise.
Topics: Adult; Blood Pressure; Body Fluids; Body Weight; Cardiac Output; Female; Heart Rate; Hemodynamics; H | 1983 |
Effect of endothelium on diabetes-induced changes in constrictor responses mediated by 5-hydroxytryptamine in rat aorta.
Topics: Amphetamines; Animals; Aorta; Arginine; Body Weight; Diabetes Mellitus, Experimental; Endothelium; I | 1993 |
Effect of ketanserine in cyclosporine-induced renal dysfunction in rats.
Topics: Animals; Body Weight; Creatinine; Cyclosporine; Female; Immunosuppressive Agents; Ketanserin; Kidney | 1995 |
Modulation of serotonin binding sites in the brain of the Djungarian hamster, Phodopus sungorus, during adaptation to a short photoperiod.
Topics: Adaptation, Physiological; Aging; Animals; Body Weight; Brain Chemistry; Cerebral Cortex; Cholestero | 1993 |
Vascular interaction between 5-hydroxytryptamine and 15-lipoxygenase metabolites of arachidonic acid.
Topics: Animals; Arachidonate 15-Lipoxygenase; Arachidonic Acids; Body Weight; Dogs; Female; Hydroxyeicosate | 1993 |
Attenuated 5-HT2 receptor-mediated responses in hindquarters of diabetic rats.
Topics: Animals; Arachidonic Acid; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Experiment | 1995 |
Enhancement of 5-hydroxytryptamine-stimulated phosphoinositide hydrolysis in the rat cerebral cortex by repeated immobilization stress.
Topics: Animals; Body Weight; Cerebral Cortex; Hydrolysis; Imipramine; Immobilization; Ketanserin; Male; Pho | 1995 |
Repeated DOI and SR 46349B treatments do not affect elevated plus-maze anxiety despite opposite effects on cortical 5-HT2A receptors.
Topics: Amphetamines; Animals; Anxiety; Behavior, Animal; Body Weight; Cerebral Cortex; Female; Fluorobenzen | 1997 |
Does chronic ketanserin treatment enhance bradycardia in old rats by serotonergic blockade?
Topics: Adrenergic alpha-Agonists; Aging; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Bra | 1998 |
Chronic effects of triiodothyronine in combination with imipramine on 5-HT transporter, 5-HT(1A) and 5-HT(2A) receptors in adult rat brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents, Tricyclic; Body Weight; Brai | 2001 |
Supersensitivity of atherosclerotic rabbit aorta to ergometrine is mediated by 5-HT2 receptors.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cyproheptadine; Ergonovine; In Vitro Techni | 1989 |
Effects of chronic oral administration of the antidepressants, desmethylimipramine and zimelidine on rat cortical GABAB binding sites: a comparison with 5-HT2 binding site changes.
Topics: Animals; Antidepressive Agents; Body Weight; Cerebral Cortex; Desipramine; Hippocampus; Ketanserin; | 1988 |